Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 6/20 | 0.53 |
| ▸ | PTPRG | P23470 | 4/20 | 0.49 |
| ▸ | PTPRC | P08575 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096488 | 0.79 | RHEB (0.51) | RHEBMAPTCYP1A2CYP2D6 | |
| SCHEMBL23709577 | 0.75 | RHEB (0.71) | RHEB | |
| SCHEMBL11227010 | 0.71 | PTPRG (0.61) | PTPRGPTPRCMAPTCYP1A2CYP2D6 | |
| SCHEMBL2116708 | 0.71 | RHEB (0.51) | RHEB | |
| SCHEMBL20535328 | 0.70 | RHEB (1.00) | RHEB | |
| SCHEMBL23702468 | 0.68 | RHEB (1.00) | RHEBMAPT | |
| SCHEMBL11702592 | 0.68 | PTPRG (0.47) | PTPRGPTPRCMAPTCYP1A2CYP2D6 | |
| SCHEMBL28872529 | 0.68 | RHEB (0.76) | RHEB | |
| SCHEMBL10613968 | 0.67 | RHEB (0.47) | RHEBMAPT | |
| Hydrochloric Acid SCHEMBL11249222 | 0.67 | PTPRG (0.46) | PTPRGPTPRCMAPTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | RHEB 1/4885PTPRG 2321/4885PTPRC 806/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | RHEB 1/4885PTPRG 3843/4885PTPRC 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.